CSIMarket
 


Enzymotec Ltd.  (ENZY)
Other Ticker:  
 
 

ENZY's Revenue Growth by Quarter and Year

Enzymotec Ltd.'s Revenue results by quarter and year




ENZY Revenue (in millions $) FY 2016 FY 2015 FY 2014 FY 2013
IV Quarter December 47.70 50.39 47.10 0.00
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   47.70 50.39 47.10 0.00



ENZY Revenue fourth quarter 2016 Y/Y Growth Comment
Enzymotec Ltd. reported decrease in Revenue in the fourth quarter 2016 by -5.35% to $ 47.70 millions, from the same quarter in 2015.
This represents worst decline in recent Company history.

Looking into fourth quarter 2016 results within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue growth. While Enzymotec Ltd.' s Revenue decline of -5.35% ranks overall at the positon no. 2560 in the fourth quarter 2016.




ENZY Revenue ( Y/Y Growth %) 2016
2015 2014 2013
IV Quarter December -5.35 % 6.99 % - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   -5.35 % 6.99 % - -

Financial Statements
Enzymotec Ltd.'s fourth quarter 2016 Revenue $ 47.70 millions ENZY's Income Statement
Enzymotec Ltd.'s fourth quarter 2015 Revenue $ 50.39 millions Quarterly ENZY's Income Statement
New: More ENZY's historic Revenue Growth >>


ENZY Revenue (Quarter on Quarter Growth %)

2016
2015 2014 2013
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   -5.35 % 6.99 % - -




Revenue fourth quarter 2016 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #298
Overall #2560

Revenue Y/Y Growth Statistics
High Average Low
6.98 % 0.82 % -5.35 %
(Dec 31 2015)   (Dec 31 2016)
Revenue fourth quarter 2016 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #298
Overall #2560
Revenue Y/Y Growth Statistics
High Average Low
6.98 % 0.82 % -5.35 %
(Dec 31 2015)   (Dec 31 2016)

Revenue by Quarter for the Fiscal Years 2013, 2014, 2015, 2016

Enzymotec Ltd.'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENZY's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENZY's IV. Quarter Q/Q Revenue Comment


Enzymotec Ltd.'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2016)
12 Months Ending
0
12 Months Ending
(Dec 31 2015)
12 Months Ending
0
12 Months Ending
(Dec 31 2014)
Cumulative Revenue 12 Months Ending $ 47.70 $ 0.00 $ 50.39 $ 0.00 $ 47.10
Y / Y Revenue Growth (TTM) -5.35 % - 6.98 % - -
Year on Year Revenue Growth Overall Ranking # 2618 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -5.35 % - 6.98 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 2425 # 0 # 0 # 0 # 0




Cumulative Revenue growth Comment
Enzymotec Ltd. showed decline, but improvement compare to trailing twelve month Revenue decrease in 0. If the fiscal year would end in Dec 31 2016, Enzymotec Ltd.'s annual Revenue improvement would be -5.35% year on year to $48 millions.

In the Healthcare sector 348 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2618.

Revenue TTM Q/Q Growth Statistics
High Average Low
-5.35 %
-5.35 %
-5.35 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 58
Healthcare Sector # 349
Overall # 2618

Revenue TTM Y/Y Growth Statistics
High Average Low
-5.35 %
-5.35 %
-5.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 298
S&P 500 # 2425
Cumulative Revenue growth Comment
Enzymotec Ltd. showed decline, but improvement compare to trailing twelve month Revenue decrease in 0. If the fiscal year would end in Dec 31 2016, Enzymotec Ltd.'s annual Revenue decline would be -5.35% year on year to $48 millions.

In the Healthcare sector 348 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2618.

Revenue TTM Q/Q Growth Statistics
High Average Low
-5.35 %
-5.35 %
-5.35 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 58
Healthcare Sector # 349
Overall # 2618

Revenue TTM Y/Y Growth Statistics
High Average Low
-5.35 %
-5.35 %
-5.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 298
S&P 500 # 2425




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENZY's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ENZY's Competitors
Revenue Growth for Enzymotec Ltd.'s Suppliers
Revenue Growth for ENZY's Customers

You may also want to know
ENZY's Annual Growth Rates ENZY's Profitability Ratios ENZY's Asset Turnover Ratio ENZY's Dividend Growth
ENZY's Roe ENZY's Valuation Ratios ENZY's Financial Strength Ratios ENZY's Dividend Payout Ratio
ENZY's Roa ENZY's Inventory Turnover Ratio ENZY's Growth Rates ENZY's Dividend Comparisons



Companies with similar Revenue decline for the quarter ending Dec 31 2016 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2016
Acer Therapeutics Inc 0.00%$ 0.000 millions
Phibro Animal Health Corporation-0.09%$ -0.091 millions
Misonix Inc -0.15%$ -0.149 millions
Abaxis Inc-0.20%$ -0.197 millions
Opko Health Inc -0.25%$ -0.254 millions
Magellan Health inc -0.42%$ -0.422 millions
Quidelortho Corp-0.63%$ -0.629 millions
Tandem Diabetes Care Inc -0.71%$ -0.714 millions
Meridian Bioscience Inc -0.74%$ -0.744 millions
Merck and Co Inc -0.98%$ -0.979 millions
Bruker Corporation-1.65%$ -1.652 millions
Alpha Pro Tech Ltd -1.87%$ -1.874 millions
Becton Dickinson And Company-2.14%$ -2.143 millions
Brookdale Senior Living Inc -2.17%$ -2.172 millions
Sangamo Therapeutics Inc -2.18%$ -2.182 millions
Haemonetics Corporation-2.38%$ -2.375 millions
Encision Inc -2.74%$ -2.739 millions
Pfizer Inc-2.99%$ -2.990 millions
Alerislife Inc -3.09%$ -3.090 millions
Tenet Healthcare Corp-3.68%$ -3.676 millions
Chembio Diagnostics Inc -3.75%$ -3.754 millions
Fate Therapeutics Inc -4.55%$ -4.554 millions
Adicet Bio Inc -4.65%$ -4.649 millions
Reshape Lifesciences Inc -4.77%$ -4.765 millions
Owens and Minor inc-4.81%$ -4.805 millions
Nektar Therapeutics-4.88%$ -4.877 millions
Msa Safety Incorporated-5.19%$ -5.187 millions
Spark Therapeutics Inc -5.20%$ -5.204 millions
Biolase Inc -5.21%$ -5.208 millions
Rockwell Medical inc -5.26%$ -5.256 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com